Cargando…

Me-Better Drug Design Based on Nevirapine and Mechanism of Molecular Interactions with Y188C Mutant HIV-1 Reverse Transcriptase

In this paper, the Y188C mutant HIV-1 reverse transcriptase (Y188CM-RT) target protein was constructed by homology modeling, and new ligands based on nevirapine (NVP) skeleton were designed by means of fragment growth. The binding activity of new ligands to Y188CM-RT was evaluated by structural anal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yan, Wang, Aidong, Wang, Jianhua, Wu, Xiaoran, Sun, Yijie, Wu, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659058/ https://www.ncbi.nlm.nih.gov/pubmed/36364174 http://dx.doi.org/10.3390/molecules27217348

Ejemplares similares

HIV-1 reverse transcriptase complex with DNA and nevirapine reveals nonnucleoside inhibition mechanism
por: Das, Kalyan, et al.
Publicado: (2012)

N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance
por: Yap, Soo-Huey, et al.
Publicado: (2007)

HIV-1 CRF08_BC mutants resistant to reverse transcriptase inhibitors
por: Wu, Hao, et al.
Publicado: (2014)

Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models
por: Mastan, SK, et al.
Publicado: (2009)

APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants
por: Dwivedi, Richa, et al.
Publicado: (2022)

Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals
por: Mbuagbaw, Lawrence, et al.
Publicado: (2016)

Approved HIV reverse transcriptase inhibitors in the past decade
por: Li, Guangdi, et al.
Publicado: (2022)

Design and synthesis of tetrahydrophthalimide derivatives as inhibitors of HIV-1 reverse transcriptase
por: Penta, Ashok, et al.
Publicado: (2013)

Structure of the HIV-1 reverse transcriptase Q151M mutant: insights into the inhibitor resistance of HIV-1 reverse transcriptase and the structure of the nucleotide-binding pocket of Hepatitis B virus polymerase
por: Nakamura, Akiyoshi, et al.
Publicado: (2015)

Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design
por: Bauman, Joseph D., et al.
Publicado: (2008)

Correction: Design and synthesis of tetrahydrophthalimide derivatives as inhibitors of HIV-1 reverse transcriptase
por: Penta, Ashok, et al.
Publicado: (2013)

1252. A Real-World Observational Study on HIV-Infected Patients who Switched from Nevirapine + 2 Nucleoside Reverse Transcriptase Inhibitors to Dolutegravir/Lamivudine in British Columbia, Canada
por: de Wet, Joss, et al.
Publicado: (2022)

Molecular Docking Studies of Marine Diterpenes as Inhibitors of Wild-Type and Mutants HIV-1 Reverse Transcriptase
por: Miceli, Leonardo A., et al.
Publicado: (2013)

M-MuLV reverse transcriptase: Selected properties and improved mutants
por: Oscorbin, Igor P., et al.
Publicado: (2021)

Aptamers that recognize drug-resistant HIV-1 reverse transcriptase
por: Li, Na, et al.
Publicado: (2008)

Aptamers that recognize drug-resistant HIV-1 reverse transcriptase
por: Li, Na, et al.
Publicado: (2009)

Fidelity of classwide-resistant HIV-2 reverse transcriptase and differential contribution of K65R to the accuracy of HIV-1 and HIV-2 reverse transcriptases
por: Álvarez, Mar, et al.
Publicado: (2017)

NMR characterization of HIV-1 reverse transcriptase binding to various non-nucleoside reverse transcriptase inhibitors with different activities
por: Thammaporn, Ratsupa, et al.
Publicado: (2015)

Reverse Transcriptase and Cellular Factors: Regulators of HIV-1 Reverse Transcription
por: Warren, Kylie, et al.
Publicado: (2009)

Docking study of HIV-1 reverse transcriptase with phytochemicals
por: Seal, Abhik, et al.
Publicado: (2011)

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
por: Smith, Steven J., et al.
Publicado: (2014)

Asymmetric conformational maturation of HIV-1 reverse transcriptase
por: Zheng, Xunhai, et al.
Publicado: (2015)

Architecture of an HIV-1 reverse transcriptase initiation complex
por: Larsen, Kevin P., et al.
Publicado: (2018)

HIV-1 Protease, Reverse Transcriptase, and Integrase Variation
por: Rhee, Soo-Yon, et al.
Publicado: (2016)

Telomerase reverse transcriptase and neurodegenerative diseases
por: Yu, Xin, et al.
Publicado: (2023)

Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death
por: Heck, Carley J. S., et al.
Publicado: (2020)

Utilization of a Deoxynucleoside Diphosphate Substrate by HIV Reverse Transcriptase
por: Garforth, Scott J., et al.
Publicado: (2008)

The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance
por: Acosta-Hoyos, Antonio J., et al.
Publicado: (2010)

Cis-Allosteric Regulation of HIV-1 Reverse Transcriptase by Integrase
por: Masuda, Takao, et al.
Publicado: (2022)

Targeting the Structural Maturation Pathway of HIV-1 Reverse Transcriptase
por: Kirby, Thomas W., et al.
Publicado: (2023)

Nevirapine Resistance and Breast-Milk HIV Transmission: Effects of Single and Extended-Dose Nevirapine Prophylaxis in Subtype C HIV-Infected Infants
por: Moorthy, Anitha, et al.
Publicado: (2009)

Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan
por: Wu, Pei-Ying, et al.
Publicado: (2017)

Induction with Lopinavir-Based Treatment Followed by Switch to Nevirapine-Based Regimen versus Non-Nucleoside Reverse Transcriptase Inhibitors-Based Treatment for First Line Antiretroviral Therapy in HIV Infected Children Three Years and Older
por: Alvarez-Uria, Gerardo, et al.
Publicado: (2014)

A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants
por: Johnson, Barry C, et al.
Publicado: (2012)

Prediction of Mutational Tolerance in HIV-1 Protease and Reverse Transcriptase Using Flexible Backbone Protein Design
por: Humphris-Narayanan, Elisabeth, et al.
Publicado: (2012)

Inhibitory effect of aqueous dandelion extract on HIV-1 replication and reverse transcriptase activity
por: Han, Huamin, et al.
Publicado: (2011)

Nevirapine induced exfoliative dermatitis in an HIV-infected patient
por: Bhandarkar, Anoosha P., et al.
Publicado: (2011)

A reverse transcriptase ribozyme
por: Samanta, Biswajit, et al.
Publicado: (2017)

Telomerase Reverse Transcriptase (TERT) is a Therapeutic Target of Oleanane Triterpenoid CDDO-Me in Prostate Cancer
por: Liu, Yongbo, et al.
Publicado: (2012)

Telomerase reverse transcriptase in the regulation of gene expression
por: Zhou, Junzhi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ilkmve48ohs1sglrc6j7av4ra4